Media room

The same professional record wherever it is introduced

Development Scale Review

Fictional editorial demonstration

What a quantity multiplier cannot explain

In this invented interview, I discuss why a move between engineering scales requires a question about equipment and material conditions. The example retains the twelve-week programme, its cost and the six-week movement in the investment decision. I distinguish the evidence for a further development route from validation or release authority, and explain why receiving specialists should participate before an assumption becomes a fixed schedule.

Transfer Reasoning Journal

Fictional editorial demonstration

When the recipient can explain the choice

This illustrative conversation examines a site handover whose documents were available before the receiving team could explain an important process rationale. I describe joint technical preparation, the time it required and the need to retain rejected routes. The discussion considers how knowledge can survive a change of personnel while preserving formal records and the authority needed before a process is changed.

Pilot Investment Letters

Fictional editorial demonstration

Nine projects fitted; three still needed a decision

For this fictional investment feature, I set out the choice between a pilot facility and a larger line. The article keeps the three excluded development projects visible and separates the approved envelope from completed capital expenditure and operating costs. It asks how a future change in project mix could alter the recommendation, without presenting smaller equipment as inherently the better commercial choice.

Formulation Decision Review

Fictional editorial demonstration

Ending a candidate without erasing its work

This invented editorial example considers the decision to stop a formulation route after its evidence did not justify the proposed next stage. I explain why expenditure already incurred remained a historical cost, why an unapproved proposal was not a realised saving and why six specialists completed closure work before reassignment. A different concept later needed an independent rationale rather than the earlier candidate's promise.

Scientific Portfolio Notes

Fictional editorial demonstration

The forecast must learn when the programme does

In this illustrative discussion, I connect a technical portfolio decision with the commercial scenario built around it. Removing a candidate from development should also change the expectations that depended on its continuation. I describe the executive conversation needed to keep those accounts consistent and the board questions that can examine the connection without turning directors into a substitute laboratory or operating authority.

Media biography

Qinglan Yun is a fictional CTO whose career in China began in July 1993. After a chemical engineering degree at Yongcen Institute, she worked at Henlure Process Sciences before joining Lianvero Pharmaceuticals in 2001. Her roles at Lianvero progressed from formulation development lead through process development head and technical director to CTO in January 2021.

Her current remit covers 147 employees through five direct reports, with 28 contractors separately, and CNY 186 million of 2026 authority. The fictional employer is a Nanjing-headquartered oral-dose medicines manufacturer with three Chinese sites, 2,300 employees and CNY 3.2 billion revenue in 2025. Company revenue describes the business rather than her personal financial scope.

Her professional writing examines scale assumptions, the reasoning needed for site transfer and decisions to invest, defer or end a development route. She has presented technical investment matters to board discussions as an executive and has no director appointment. Her illustrative speaking and media material retain the same career, remit and limits. All outlets on this page are invented examples, not claims of real editorial coverage.

Biographies

Approved text

Short speaker biography

Qinglan Yun is a fictional China-based pharmaceutical CTO whose 33-year career connects process development with manufacturing investment. She leads 147 employees at Lianvero Pharmaceuticals and holds CNY 186 million of 2026 authority. Her speaking examines scale assumptions, technical transfer, pilot capacity and the judgement required to stop a development route. She has no director appointment.

Standard speaker biography

Qinglan Yun is the fictional CTO of Lianvero Pharmaceuticals, a Nanjing-headquartered oral-dose medicines business. Her career began in July 1993 after a chemical engineering degree and progressed through formulation leadership, process development and technical directorship. Her present remit comprises 147 employees through five direct reports, with 28 contractors separately, and CNY 186 million of 2026 authority. Her work connects development knowledge with equipment, transfer and portfolio choices while retaining the separate authority of quality, regulatory and clinical colleagues. Qinglan speaks about the assumptions behind scale, the reasoning a receiving site needs and the consequences of a smaller investment or a stopped candidate. She presents to board discussions as an executive and has not held a director seat.

Extended speaker biography

Qinglan Yun is a fictional pharmaceutical technology leader based in China. She completed a chemical engineering degree at Yongcen Institute in June 1993 and began as a process engineer at Henlure Process Sciences the following month. She joined Lianvero Pharmaceuticals in 2001, progressing through formulation development lead, head of process development and technical director before becoming CTO in January 2021. Her 33-year career concerns the relationship between development knowledge and the manufacturing commitments a company makes next.

Lianvero is presented as a Nanjing-headquartered oral-dose medicines manufacturer with sites in Nanjing, Suzhou and Wuxi, 2,300 employees and CNY 3.2 billion 2025 revenue. Qinglan's current team has 147 employees through five direct reports, plus 28 contractors separately. Her 2026 authority is CNY 186 million, divided between process development and manufacturing technology. She reports to chief executive Ruiwen Xun; quality, regulatory and clinical responsibilities retain their authorised owners.

Her illustrative cases examine engineering scale, laboratory differences, site transfer, a pilot investment and the deliberate end of a formulation candidate. Her sessions connect those choices to evidence, expenditure and the obligations left after a decision. Qinglan has presented technical investment matters to the board in an executive capacity but has never served as a director. Any prospective first appointment would require induction, relationship review and agreement on the actual calendar.

An invitation

Contact

I am open to a board or advisory discussion with a business where process knowledge and capital decisions are closely connected. I have no director appointment and would prepare carefully for a first seat, with twenty annual days considered against the actual calendar and employer consent. For speaking, I welcome audiences ready to examine a concrete development or transfer decision, including the cost of a route that was deliberately not taken.

Open to

Board appointments
Advisory roles
Speaking invitations

Write to Qinglan

office@qinglanyun.example